FDA Issues Risk Warning for Potato Chips Recall
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A recall of potato chips due to the possible presence of an undeclared allergen has been issued the second-highest risk warning by the U.S. Food and Drug Administration (FDA).
Saratoga Potato Chips LLC, based in Indiana, issued a voluntary recall for more than 2,000 bags of chips due to the undeclared presence of milk on July 7.
The FDA subsequently issued a Class II risk classification on July 15.
Newsweek contacted Saratoga Potato Chips LLC for comment by email.
Stock image. Saratoga Potato Chips LLC issued a voluntary recall for more than 2,000 bags of crisps due to the undeclared presence of milk on July 7.
Stock image. Saratoga Potato Chips LLC issued a voluntary recall for more than 2,000 bags of crisps due to the undeclared presence of milk on July 7.
Robert Michael/picture-alliance/dpa/AP Images
Why It Matters
A Class II risk classification refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA.
The recall was initiated due to the undeclared presence of milk, one of the nine major food allergens as defined in law. The others are eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame.
Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems.
What To Know
The product impacted by the recall is the following:
- J. Higgs Potato Chip Mix - 2275 bags - UPC code: 0-51933-37327-3 - best if used by date: October 5, 2025
The product was distributed to retail locations in Maryland, Kentucky, Florida and Indiana.
What People Are Saying
The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food."
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, told Newsweek previously: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
The recall is listed as ongoing, according to the FDA.
People with sensitivities or allergies to milk should not consume the affected product.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
Ibogaine by David Dardashti Warns of Kratom's ‘Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
WESTCHESTER, FL - August 4, 2025 - As the FDA intensifies its crackdown on the potent kratom compound 7-hydroxymitragynine (7-OH), the addiction treatment center Ibogaine by David Dardashti is issuing a critical warning based on alarming clinical trends. The clinic's founder, David Dardashti, is speaking out about the substance's deceptive role as a gateway to more dangerous opioids, based on a sharp increase in patients seeking treatment for kratom dependency at his facility. The recent FDA actions targeting concentrated 7-OH products—dubbed 'legal morphine' by some researchers—underscore a danger the clinical team at Ibogaine by David Dardashti sees daily. The clinic has witnessed a significant increase in patients arriving with a primary or secondary addiction to kratom, often after being misled by marketing that promotes it as a safe, herbal alternative to opioids. This firsthand clinical data forms the basis for their urgent public warning. 'We are seeing a disturbing pattern,' states David Dardashti. 'Patients come to us after starting with kratom, thinking it's a safe, natural remedy. They don't realize they are developing a true opioid dependency until it's too late. The initial effects fade, tolerance builds, and suddenly they are facing a full-blown addiction with severe withdrawals. The next logical step for many is to seek out something stronger and deadlier, like fentanyl. We are on the front lines of this trend, and it is alarming.' As referenced in recent reports, experts confirm that while the kratom leaf itself may be mild, concentrated extracts containing 7-OH are significantly more potent and act as pure opioids. This creates the dangerous cycle of dependency that the clinic observes. Users require ever-increasing doses, eventually finding that the legal substance no longer satisfies the addiction it created, driving them toward the illicit drug market. Despite the alarming trend, the team at Ibogaine by David Dardashti reports significant success in treating kratom addiction and offers a message of hope. Based on extensive clinical experience, the center has found a notable distinction in the recovery process for these patients. 'The good news in this growing crisis is that we've found that individuals dependent on kratom can be brought back to sobriety with less difficulty than those entrenched in long-term Suboxone or fentanyl use,' Dardashti explains. 'Ibogaine therapy works to reset the brain's neurotransmitters and interrupt addiction at the source. For our kratom patients, the process is often smoother and the path to a full recovery is remarkably clear. Our goal is to intervene effectively before the addiction escalates into a far more tragic story.' About Ibogaine by David Dardashti: Ibogaine by David Dardashti is a leading treatment center dedicated to helping individuals overcome chemical dependency through a unique combination of ibogaine therapy and holistic care. Founded by David Dardashti, the clinic leverages extensive clinical experience to provide a safe, medically supervised environment for profound psycho-spiritual healing and neurological reset, offering a definitive interruption to the cycle of addiction. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine by David Dardashti Warns of Kratom's 'Gateway' Dangers, Citing Alarming Trend in Patient Addiction Cases
Newsweek
an hour ago
- Newsweek
PTSD Drug Discovery May Help Patients Let Go of Trauma
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A promising new drug could help people living with post-traumatic stress disorder (PTSD) finally let go of trauma. This is the discovery of scientists at the Institute of Basic Science (IBS) and Ewha Womans University in South Korea who have identified a new brain mechanism driving the mental health condition—and a drug with the potential to counteract its effects. The team has shown for the first time that "excessive" gamma-aminobutyric acid (GABA)—the brain's primary neurotransmitter—produced by star-shaped support cells in the brain known as "astrocytes" impairs the brain's ability to extinguish fear memories. This inability to forget traumatic memories even after a long period of time is distinct to PTSD and has posed a major hurdle for treatment. Current medications targeting serotonin receptors offer limited relief for only a subset of patients, the authors said. "Current FDA-approved treatments for PTSD are mainly SSRIs, which focus on reducing general symptoms like anxiety and mood instability," study author Dr. Woojin Won told Newsweek. "However, only about 20–30 percent of patients achieve full remission, which is often unsatisfactory. Our approach is fundamentally different." Woman with head in hands in dark room. Woman with head in hands in dark room. Domepitipat/Getty Images Won continued: "While prefrontal cortex (PFC) dysfunction has been consistently reported in PTSD, the role of GABAergic mechanisms in this dysfunction has not been fully explored." The researchers found that a brain-permeable drug called KDS2010, which selectively blocks an enzyme called 'monoamine oxidase B' (MAOB) responsible for this abnormal GABA production, can reverse PTSD-like symptoms in mice. "It targets the pathological reactive astrocyte-derived GABA at the source," said Won. "Unlike traditional MAO inhibitors, which can have off-target effects and are irreversible, KDS2010 is highly selective, reversible, and brain-penetrant, making it safer and more targeted." They report the drug has already passed Phase 1 safety trials in humans, which makes it a "strong candidate" for future PTSD treatments. GABA can be a positive thing, helping to regulate motor function, sensory processing and emotional stability. It can also offer calming effects, including helping to reduce anxiety and stress by controlling overactive neurons. "However," Won explained, "GABA does not act uniformly across the brain, and its outcome varies depending on the target circuit. "While GABA is generally calming, in this context [of the researcher's findings], it was silencing a circuit that the brain needs to overcome fear. This highlights that the effect of GABA is not simply good or bad, but it critically depends on where it acts and what neural circuits are involved." Digital illustration showing brain waves and activity. Digital illustration showing brain waves and activity. selvanegra/Getty Images The study focused on the medial prefrontal cortex (mPFC), a region of the brain critical for regulating fear. It found that PTSD patients had unusually high levels of GABA and reduced cerebral blood flow in this area, based on brain imaging studies of more than 380 participants. On the other hand, GABA levels decreased in patients who showed clinical improvement, suggesting the chemical has a central role in recovery. To unearth the origin of the excess GABA, the researchers examined postmortem human brain tissue and used PTSD-like mouse models. They discovered that astrocytes, not neurons, were producing abnormal amounts of GABA via the MAOB enzyme. This astrocyte-derived GABA impaired neural activity, blocking the brain's ability to forget traumatic memories. "This inspired us to investigate astrocytic GABA dysregulation as a potential driver of PTSD pathology, and ultimately, as a novel therapeutic target," said Won. Explaining further how "excessive" GABA in PTSD is produced, he added: "Trauma and stress might increase putrescine metabolism, which raises the levels of MAOB's presubstrate, leading to more GABA production. "At the same time, the enzyme that breaks down GABA, ABAT, is reduced. Together, this combination causes the accumulation of astrocytic GABA and excessive tonic inhibition in key brain regions like the PFC." When the team administered KDS2010, "a highly selective, reversible MAOB inhibitor" developed at IBS, the mice showed normalized brain activity and were able to extinguish fear responses. The promising drug reduced GABA levels, restored blood flow in the mPFC, and re-enabled memory extinction mechanisms. This confirms astrocytic MAOB as a central driver of PTSD symptoms and MAOB inhibition as a viable therapeutic path. The researchers flagged a major challenge of the study was linking clinical findings in humans with cellular mechanisms in the lab. They addressed this by applying a "reverse translational" strategy, beginning with clinical brain scans and moving backward to identify the cellular source of dysfunction. They then confirmed the mechanism and tested drug effects in animal models. This led to a new understanding of how glial cells—non-neuronal cells long thought to be passive—actively shape psychiatric symptoms. Would this type of drug be used alongside other methods like talking therapy for PTSD? "DS2010 alone has a strong potential to restore brain function by normalizing astrocytic GABA and improving fear extinction. However, we think that combining it with psychotherapy, especially exposure-based therapy, could create even greater synergy. By reducing abnormal inhibition in fear extinction circuits, KDS2010 may help the brain become more responsive to therapeutic input," Won explained. How would it be administered? "KDS2010 is an orally available small molecule. In preclinical and early-phase clinical studies, it has been administered once daily in capsule or liquid form. This makes it highly feasible for long-term outpatient use, similar to antidepressants." What about side effects? "In the Phase 1 clinical trial, KDS2010 was found to be well tolerated, with no serious adverse effects reported, even at higher doses. This safety is largely due to its selectivity for MAOB and its reversible mechanism, which avoids the long-term enzyme compensation seen with older MAO inhibitors. Nevertheless, larger trials in PTSD patients will be needed to fully assess tolerability and any rare side effects." Won said the drug is currently undergoing Phase 2 trials for other neurological disorders, which means its safety profile is already being tested extensively in patients. "Because of this, we believe it could reach the public faster than many other new drugs. If future trials for PTSD are successful and regulatory steps proceed smoothly, it could become available within a few years. Importantly, KDS2010 is part of a broader platform that may also be useful for treating other disorders involving astrocytic dysfunction, such as Parkinson's and Alzheimer's disease." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about PTSD? Let us know via health@ Reference Yoon, S., Won, W., Lee, S., Han, K., Ha, E., Lee, J., Hyeon, S. J., Joo, Y., Hong, H., Lee, H., Song, Y., Park, K. D., Huber, B. R., Lee, J., Edden, R. A. E., Suh, M., Ryu, H., Lee, C. J., & Lyoo, I. K. (2025). Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder. Signal Transduction and Targeted Therapy, 10(1), 240.
Newsweek
an hour ago
- Newsweek
Nationwide Honey Recall Update as FDA Issues Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Food inspectors have designated a nationwide recall of hundreds of honey products as the second-highest of three risk levels. Queen Bee Gardens, a company in Wyoming, issued a voluntary recall on July 16 of hundreds of jars of its whipped honey products after internal checks raised concerns that some batches could contain small flakes of stainless steel. On August 1, the U.S. Food and Drug Administration categorized the recall as Class II. Newsweek contacted Queen Bee Gardens via its general inquiries email on Monday outside normal working hours. Why It Matters The FDA's classification of the Queen Bee Gardens recall as Class II signals a moderate health risk, indicating that use or exposure to the affected products may cause temporary or medically reversible adverse health consequences, while the probability of serious adverse health consequences is remote. What To Know Queen Bee Gardens, based in Lovell, voluntarily recalled these affected products: 129 jars of QBee Whipped Honey Raspberry with the UPC 788394182358 112 jars of QBee Whipped Honey Pure with the UPC 788394182006 24 jars of QBee Whipped Honey Huckleberry with the UPC 788394182259 According to the FDA notice, the QBee Whipped Honey Raspberry and QBee Whipped Honey Pure products have the lot codes 206235 and were made on June 23. The QBee Whipped Honey Huckleberry has the lot code 206305 and was made on June 30. The recall covers jars distributed throughout the United States. Consumers are urged to discontinue use of the affected honey immediately. Stock image shows dripping honey. Stock image shows dripping honey. Getty Images What People Are Saying The U.S. Food and Drug Administration said of the recall risk categories on its website: "Class I—a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. "Class II—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. "Class III—a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences." What Happens Next The recall of Queen Bee Gardens' honey products remains ongoing. Consumers in possession of the recalled jars are advised to discontinue use immediately and follow company or FDA guidance regarding returns or refunds. Consumers who experience any health concerns related to the ingestion of these or similar products are encouraged to consult a medical professional and report the incident to the FDA's MedWatch program.
